ViewRay, Inc. Forecasted to Post FY2017 Earnings of ($0.88) Per Share (VRAY)
ViewRay, Inc. (NASDAQ:VRAY) – Analysts at Zacks Investment Research issued their FY2017 earnings per share (EPS) estimates for ViewRay in a research report issued on Monday. Zacks Investment Research analyst A. Dushyanth forecasts that the company will earn ($0.88) per share for the year. Zacks Investment Research also issued estimates for ViewRay’s Q4 2017 earnings at ($0.18) EPS, FY2018 earnings at ($0.63) EPS, FY2019 earnings at $0.29 EPS and FY2020 earnings at ($0.08) EPS.
ViewRay (NASDAQ:VRAY) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million during the quarter, compared to analyst estimates of $18.63 million. The business’s quarterly revenue was up 2950.0% on a year-over-year basis.
VRAY has been the topic of several other research reports. Mizuho reissued a “buy” rating and issued a $12.00 price target on shares of ViewRay in a report on Monday, November 13th. ValuEngine downgraded ViewRay from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Finally, Northland Securities reissued a “buy” rating and issued a $10.00 price target on shares of ViewRay in a report on Friday, November 17th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $10.60.
Shares of ViewRay (NASDAQ:VRAY) opened at $9.52 on Wednesday. ViewRay has a 1-year low of $2.98 and a 1-year high of $10.39. The company has a current ratio of 1.59, a quick ratio of 1.20 and a debt-to-equity ratio of -1.67.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in ViewRay by 67.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,026,880 shares of the company’s stock valued at $6,644,000 after acquiring an additional 411,866 shares during the period. Pura Vida Investments LLC increased its position in ViewRay by 132.9% in the 3rd quarter. Pura Vida Investments LLC now owns 607,040 shares of the company’s stock valued at $3,497,000 after acquiring an additional 346,370 shares during the period. State Street Corp increased its position in ViewRay by 631.7% in the 2nd quarter. State Street Corp now owns 395,418 shares of the company’s stock valued at $2,555,000 after acquiring an additional 341,376 shares during the period. TIAA CREF Investment Management LLC increased its position in ViewRay by 2,447.3% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 286,365 shares of the company’s stock valued at $1,853,000 after acquiring an additional 275,123 shares during the period. Finally, RTW Investments LP increased its position in ViewRay by 33.5% in the 3rd quarter. RTW Investments LP now owns 1,020,462 shares of the company’s stock valued at $5,878,000 after acquiring an additional 256,127 shares during the period. 46.99% of the stock is currently owned by institutional investors and hedge funds.
ViewRay Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.